Literature DB >> 28187335

Insight into illness and its relationship to illness severity, cognition and estimated antipsychotic dopamine receptor occupancy in schizophrenia: An antipsychotic dose reduction study.

Philip Gerretsen1, Hiroyoshi Takeuchi2, Miracle Ozzoude3, Ariel Graff-Guerrero4, Hiroyuki Uchida5.   

Abstract

Little is known about the influence of D2 receptor occupancy on impaired insight into illness (III)-a core feature of schizophrenia. III is associated with illness severity and cognitive dysfunction. Comparably, supratherapeutic D2 receptor occupancy can impair cognition. However, it is unclear how illness severity, cognition, and D2 receptor occupancy interact to influence III in schizophrenia. The aim of this study was to explore the influence of antipsychotic dose reduction on the relationships of illness severity and cognition to III. III was assessed at baseline and 28 weeks post-antipsychotic dose reduction in 16 participants with schizophrenia and plasma antipsychotic concentrations. III was assessed primarily with the Schedule for the Assessment of Insight-Japanese version, and secondarily with the Positive and Negative Syndrome Scale item G12. Correlation and regression analyses were performed to explore III's relationship to illness severity, cognition, and estimated D2 receptor occupancy (Est.D2). Cognition and Est.D2 predicted III at baseline. At 28 weeks post-reduction, illness severity and Est.D2 predicted III. Our findings suggest a complex relationship may exist among III, illness severity, cognition and Est.D2. At higher D2 receptor occupancies, III is influenced by cognitive dysfunction, whereas, at lower occupancies, illness severity has a stronger effect on III.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28187335     DOI: 10.1016/j.psychres.2017.01.090

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  2 in total

1.  The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole.

Authors:  Sangho Shin; Seoyoung Kim; Seongho Seo; Jae Sung Lee; Oliver D Howes; Euitae Kim; Jun Soo Kwon
Journal:  Transl Psychiatry       Date:  2018-04-24       Impact factor: 6.222

2.  Risk factors for readmission in schizophrenia treated with combined psychoeducation and standard therapy.

Authors:  Satoru Sugisawa; Tatsuya Kurihara; Yukako Nakano; Toshiaki Tsuneoka; Hiroaki Koya; Tsutomu Nagai; Tomohiro Ikeda; Naoko Fujisawa; Atsuko Inamoto; Akira Iwanami
Journal:  Neuropsychopharmacol Rep       Date:  2022-01-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.